Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + apatinib + S-1 conversion therapy for gastric cancer with positive peritoneal cytology
ChiCTR1800019090Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Oct 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel, Rivoceranib and tegafur in gastric cancer (GC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: R0 resection rate and Conversion to negative rate. Started Oct 2018; status: recruiting.
02
Drugs
paclitaxelRivoceranibtegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800019090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019090.